competitive landscape of Gene Therapy , and assesses key developments in delivery vector technology , and challenges and advances associated with the production of such vectors .
Scope of the Gene therapy analysis report :
Despite 25 years of clinical research , only a few gene therapies of all types have reached the market globally , and none have achieved strong clinical or commercial success –
– Why do gene therapies still occupy only a minimal market share in their respective indications ? – What can be learned from the gene therapies that have already reached the market ? A number of different viral and non-viral vector types are currently in development for the delivery of gene therapies – – What are the relative advantages and disadvantages of each vector type and which hold the most promise ? – What proportion of the overall gene therapy R & D pipeline is occupied by each vector type ?
The current pipeline for gene therapies is diverse in terms of the approaches and vectors covered ; 50 % are gene silencing therapies , while 31 % involve the insertion of a functional gene – – In which therapy areas is there the highest level of R & D activity for gene therapies ? – At which stage of development does the majority of pipeline gene therapies reside ? – What is the proportion of the pipeline occupied by each intervention and vector type overall ? A number of companies are currently actively developing pipeline gene therapies , including private , public and institutional enterprises – – How do gene therapies fit into the overall portfolios of these companies ? – What is the level of involvement in gene therapy research from the top 20 Big Pharma companies ?
Get 15 % Discount on Single User License of Gene Therapies : A Diverse Range of Technologies with a Promising Long-Term Outlook Market Research Report at – www . absolutereports . com / enquiry / request-discount / 10075327
Offer valid till 1 st July 2016
The report will allow to –
– Understand the current status of the field of therapeutic gene therapies , and the relative clinical and commercial success of currently marketed products , comprising Glybera , Kynamro , Macugen , Vitravene , Gendicine , Oncorine , and